Sanofi (SNY)

Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness  Recommendation based on phase 2/3 study demonstrating up to 96 percent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness The therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens and help support the World Health Organization's (WHO) goal of eliminating the disease by 2030 Sanofi will donate the medicine to WHO through its philanthropic arm Foundation S Kinshasa / Paris / Geneva / Amsterdam – February 27, 2026.

• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?

Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the US to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut and respiratory system diseases that affect a broad range of patients, from infants to elderly adults Paris and Tarrytown, NY, February 24, 2026. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery.

Texas Attorney General Ken Paxton on Thursday sued Sanofi for allegedly "bribing" providers to prescribe its medications over alternatives.

Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026.

Teva and Sanofi SA (NASDAQ: SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.

Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.

French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season Data published in The Lancet Infectious Diseases and to be presented at RSVVW '26 conference in Rome Paris, February 16, 2026. A universal respiratory syncytial virus (RSV) immunization program using Beyfortus (nirsevimab) was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants immunized during their first season, according to a new study published in  The Lancet Infectious Diseases.

Atria Investments Inc trimmed its position in Sanofi (NASDAQ: SNY) by 12.2% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 117,300 shares of the company's stock after selling 16,347 shares during the period. Atria Investments Inc's holdings in Sanofi were worth $5,537,000 as of

Assetmark Inc. boosted its stake in shares of Sanofi (NASDAQ: SNY) by 25.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 357,172 shares of the company's stock after purchasing an additional 71,356 shares during the period. Assetmark Inc.'s holdings

Caprock Group LLC acquired a new stake in shares of Sanofi (NASDAQ: SNY) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 27,229 shares of the company's stock, valued at approximately $1,347,000. A number of other institutional investors and

Weekly Market HighlightsWeekly breadth was slightly negative with 4,703 advancers versus 4,832 decliners, even as 963 stocks gained more than 10% and 1,151 fel